China: 2020’s Biggest Biotech IPO in Profile
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
Address: 22F, N.138 Pudong Avenue
Shanghai 200120 P.R. China ,China
Tel: +86 21 5888 2200
Web: http://www.boehringer-ingelheim.com.cn/
Entering the Chinese market in 1994, Boehringer Ingelheim investment ushered in vigorous development. Boehringer Ingelheim has excellent products in the prescription drugs, consumer self-care medicines and animal health field in the Chinese market and are widely recognized by consumers.
Since 2002, the company has been based in Shanghai. The Zhangjiang Hi-Tech Park factory was built to demonstrate the Boehringer Ingelheim’s determination to further establish itself in China. The Zhangjiang plant has introduced the world’s most advanced pharmaceutical equipment, design and management standards to the country and is comparable to Boehringer Ingelheim plants in any part of the world. The factory operates in strict accordance to international GMP standards. Boehringer Ingelheim’s investment in China amounts $ 29,000,000. The Company has offices in Shanghai, in Beijing, Guangzhou, Shenyang, Chengdu, Nanjing, Hangzhou and has also set up branches in other places, employing a total of more than 2,000 people.
Boehringer Ingelheim’s main business in China includes prescription drugs, consumer self-care medicines and animal health. The business scope encompasses all of the country’s major cities and regions. The company will continue to pursue new drug and disease treatment programs and Boehringer Ingelheim products have gained an excellent reputation in the market, benefitting millions of patients.
Looking ahead, Boehringer Ingelheim Shanghai looks forward to even greater success in the Chinese market, including in the field of human medicine, the company wants to be the key leader in the respiratory, cardiovascular, central nervous system, diabetes and cancer fields. as well as animal health.
With a solid foundation built up over more than a century, Boehringer Ingelheim strives to make greater contributions to Chinese medical and health undertakings.
respiratory, cardiovascular, central nervous system, diabetes, oncology
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
A roundup of the latest from Chinese pharma, including Green Valley’s upcoming US trial for an Alzheimer’s drug inspired by algae; Samsung Biologics expansion in China; Fosun Pharma’s halt to…
While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in…
Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and therapies as it becomes a clinical-phase company.…
The collaboration between BioNTech and Pfizer on a COVID-19 vaccine candidate based on mRNA technology continues apace, with hopes for an emergency approval in late-2019. In China, home to 1.4…
The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio Series D financing round for small-molecule drugs, as…
Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology collaboration with AbbVie, Jiangsu Hengrui’s latest deal with US biotech Dyadic,…
While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception in the 1980s, and presently, biologics represent…
Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios and developing clinical development capabilities, kickstarting their growth.…
The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and biotech Antengene’s potential USD 200 million IPO in Hong Kong.…
The partnership between global pharma giant Eli Lilly and Chinese biotech Innovent Biologics, first initiated in March 2015, continues to bear dividends for both parties. The recent announcement that Lillly…
Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist approach to teambuilding helps it stand out from…
See our Cookie Privacy Policy Here
